Sab biotherapeutics announces private placement of up to $130 million to advance development of lead drug candidate for type 1 diabetes

Funding to support clinical advancement of sab-142, a potential disease-modifying treatment financing led by ra capital management, with participation from bvf partners, sessa capital, commodore capital, rtw investments, marshall wace, and the jdrf t1d fund sioux falls, s.d., oct. 02, 2023 (globe newswire) -- sab biotherapeutics (nasdaq: sabs), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced the company has entered into a securities purchase agreement (the “securities purchase agreement”) with certain accredited investors (the “investors”), pursuant to which the company agreed to issue and sell shares of preferred stock in a private placement (the “offering”).
SABS Ratings Summary
SABS Quant Ranking